Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
Rhea-AI Summary
Edgewise Therapeutics (Nasdaq: EWTX) announced that Kevin Koch, Ph.D., President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 8:15 am PT (11:15 am ET). The presentation will be webcast live and available for replay for a limited time on the company's Events & Presentations page. Attendees are advised to connect several minutes early to ensure a timely connection.
Positive
- None.
Negative
- None.
News Market Reaction – EWTX
On the day this news was published, EWTX declined 2.67%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $71M from the company's valuation, bringing the market cap to $2.58B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
EWTX slipped -0.76% with light volume while close biotech peers were mixed: several down modestly (e.g., PHVS -6.04%, VERA -2.38%, VRDN -1.32%, ARDX -1.14%) and AUPH up 0.86%. Moves do not indicate a unified sector reaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 24 | Clinical trial update | Positive | +25.5% | Positive Phase 2 EDG-7500 data with favorable interim safety in HCM. |
| Dec 02 | Inducement grants | Neutral | -9.1% | Equity inducement grant for new hire under 2024 Inducement Equity Plan. |
| Nov 20 | Board appointment | Positive | -0.4% | Appointment of commercial executive Christopher Martin to Board of Directors. |
| Nov 12 | Inducement grants | Neutral | -1.4% | Inducement stock options and RSUs granted to incoming CFO Michael Nofi. |
| Nov 10 | CFO transition | Positive | +6.5% | Appointment of new CFO and retirement of prior CFO with planned transition. |
Major clinical data (EDG-7500 Phase 2) drew a strong positive move, while governance and inducement grant news often saw muted or negative reactions, with the CFO appointment an exception that aligned positively.
Over the last few months, Edgewise released several catalysts. On Nov 6, 2025, its Q3 2025 10-Q detailed a $40.7M net loss but highlighted strong liquidity of $563.3M and multiple advancing clinical programs. Subsequent filings and 8-Ks in November documented the appointment of a new CFO and a commercial-focused director, plus related equity awards and inducement grants. Clinical momentum was reinforced on Dec 24, 2025 with positive Phase 2 EDG-7500 safety and efficacy signals. Today’s conference presentation fits into this ongoing communication cadence rather than marking a discrete data or financing event.
Market Pulse Summary
This announcement highlights Edgewise’s upcoming presentation at the J.P. Morgan Healthcare Conference on January 13, 2026, signaling continued engagement with the healthcare investor community. In recent months the company reported strong liquidity of $563.3M alongside advancing muscular and cardiovascular programs and key leadership additions. Investors may watch for any new clinical, commercial, or financial details shared at the conference that build on these prior disclosures.
AI-generated analysis. Not financial advice.
Event Details:
Date: Tuesday, January 13, 2026
Time: 8:15 am PT (11:15 am ET)
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn and X.
View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-on-january-13-2026-302653408.html
SOURCE Edgewise Therapeutics
FAQ
When will Edgewise Therapeutics (EWTX) present at the J.P. Morgan Healthcare Conference?
Who is presenting for Edgewise Therapeutics (EWTX) at the January 13, 2026 conference?
How can investors watch the Edgewise (EWTX) presentation on January 13, 2026?
What time should I join the live webcast for Edgewise (EWTX) to ensure a timely connection?
Will the Edgewise (EWTX) webcast from the J.P. Morgan conference be available after January 13, 2026?
Where can I find the webcast link for Edgewise Therapeutics (EWTX) presentation on January 13, 2026?
